Key result
Emerging biological and tissue-engineering technologies offer potential solutions for treating chondral defects, labral tears, and ligamentum teres deficiency in hip arthroscopy.
Answers are grounded in this paper and cite their sources.
This review outlines emerging biological and tissue-engineering technologies for treating hip joint defects and their potential future impact on hip arthroscopy.
As the field of hip arthroscopy continues to evolve, the biological understanding of orthopaedic tissues, namely articular cartilage, labral fibro-cartilage and the ligamentum teres continues to expand. Similarly, the need for biological solutions for the pre-arthritic and early arthritic hip continues to be a challenge for the sports medicine surgeon and hip arthroscopist. This article outlines existing biological and tissue-engineering technologies, some being used in clinical practice and other technologies being developed, and how these biological and tissue-engineering principals may one day influence the practice of hip arthroscopy. This review of hip literature is specific to emerging biological technologies for the treatment of chondral defects, labral tears and ligamentum teres deficiency. Of note, not all of the technologies described in this article have been approved by the United States Food and Drug Administration and some of the described uses of the approved technologies should be considered 'off-label' uses.
No takes yet. Share an insight, caveat, or question.
Stubbs et al. (2015) conducted a review in Pre-arthritic and early arthritic hip conditions (chondral defects, labral tears, ligamentum teres deficiency). Biological and tissue-engineering technologies was evaluated. Emerging biological and tissue-engineering technologies offer potential solutions for treating chondral defects, labral tears, and ligamentum teres deficiency in hip arthroscopy.
Synapse has enriched 10 related papers. Consider them for comparative context: